Cambridgeshire & Peterborough
Stroke-Care Improvement Programme

In partnership with Cambridge University Healthcare Trust, EGMSA (East Genomic Medicine Service Alliance) and ECLIPSE (Equality of Care Led Insights for Patient Safety & Engagement)

Practice Pro-Forma

Project Information:

We’d like to invite you to take part in an innovative local service improvement programme sponsored by Cambridge University Healthcare Trust and the East Genomic Medicine Service Alliance (EGMSA). This work is being carried out by Eclipse on behalf of the sponsor.

We are seeking your permission to allow Eclipse (the contracted NHS Population Health Provider) to contact relevant patients on behalf of the practice and invite them to participate.

The project is looking at stroke care – and specifically, the variable efficacy of Clopidogrel at preventing secondary events – in light of known ethnic differences in metabolism of this drug and a possible resulting impact on its effectiveness.

This project is in line with the latest NICE guidance on possible pharmacogenomic testing in stroke patients.

Proposal:

Eclipse would anonymously contact relevant practice patients (those coded as having had a stroke/TIA whilst on clopidogrel in the last 3 years), inviting them to complete a questionnaire about their and their families ethnic heritage.

Cohort and Engagement:

Patients identified as being likely to possess an elevated risk of having a ‘poor metaboliser status’ – in line with known scientific analysis (predominantly those with a South Asian heritage) will be invited to receive a buccal swab test (facilitated by Eclipse) and to have their genotype analysed (using the approved Genedrive Point of Care CYP2C19 analyser) and the result returned to them.

Data Preferences:

For those practices that agree to it – Eclipse would send information about the relevant patient ‘metaboliser status’ read-code directly back to the practice – for clinical staff to insert into the patient record if agreed.

Eclipse would give practices information about what local prescribing guidance recommends for those patients identified as have poor metaboliser status (eg, a switch from Clopidogrel to Prasugrel or Ticagrelor)

All data security precautions and permissions are adhered to at all times and in-line with standard NHSE requirements.

Resource Requirements:

  • No additional practice resource, staff time, or cost is anticipated in order for you to take part in this project (except that associated with the possible coding of a patient’s testing status, and the possible antiplatelet drug switching)

  • All patient engagement activity (including the initial contact, the recording of patient questionnaire responses, the invitation for testing, and the communication of the result, will be carried out by Eclipse and not involve practice time/resource.

In order for us to record your agreement to participate, please complete the contact details below: